NCT00004902View on ClinicalTrials.gov

Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 1998

Primary Completion Date

November 30, 1999

Study Completion Date

November 30, 1999

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

tocladesine

Trial Locations (1)

60611

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00004902 - Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter